摘要:
The invention relates to pharmaceutical compositions containing an active ingredient at least one known organosilane derviative of formula (I), wherein R 1 represents a hydrogen or halogen atom ; A represents oxygen or =CH 2 or NR group, wherein R represents a hydrogen atom or a C 1-4 alkyl group ; m is 1, 2 or 3; and n is 1 or 2, or a pharmaceutically acceptable salt thereof in admixture with one or more pharmaceutically acceptable carriers, excipients and/or diluents. The compositions of the invention possess muscle relaxant and antiparkinsonic effects, thus, they can be used for the treatment or prevention of diseases and conditions accompanied by hyperreflexia of the central nervous system and/or an increase of the muscular tone as well as nervous system injuries, degenerative nervous system disoders, sclerosis multiplex, myelopathies, rachicele, articular pains and Parkinson's disease in mammals including man.
摘要:
The invention relates to pharmaceutical compositions containing an active ingredient at least one known organosilane derviative of formula (I), wherein
R 1 represents a hydrogen or halogen atom ; A represents oxygen or =CH 2 or NR group, wherein R represents a hydrogen atom or a C 1-4 alkyl group ; m is 1, 2 or 3; and n is 1 or 2,
or a pharmaceutically acceptable salt thereof in admixture with one or more pharmaceutically acceptable carriers, excipients and/or diluents. The compositions of the invention possess muscle relaxant and antiparkinsonic effects, thus, they can be used for the treatment or prevention of diseases and conditions accompanied by hyperreflexia of the central nervous system and/or an increase of the muscular tone as well as nervous system injuries, degenerative nervous system disoders, sclerosis multiplex, myelopathies, rachicele, articular pains and Parkinson's disease in mammals including man.
摘要:
The invention relates to novel organosilanes of the formula (I)
wherein m is 1, 2 or 3; R¹ and/or R² represents hydrogen, a straight or branched C₁₋₄alkyl, C₁₋₄alkoxy, C₅₋₇cycloalkyl group or halogen; B represents a 5- or 6-membered saturated or unsaturated heterocyclic group which contains one or more nitrogen atoms and optionally an additional oxygen or sulfur atom or -NH or -NR group, wherein R represents a C₁₋₅alkyl or (C₁₋₅ alkyl)carbonyl group, said heterocyclic group being bound through a nitrogen atom to the (CH₂) m group and optionally substituted by a C₁₋₄alkyl or (C₁₋₄alkoxy)carbonyl group; and acid addition salts thereof. The compounds of the formula (I) show a strong muscle relaxant effect and antiparkinsonic properties; thus, they are useful for the treatment of Parkinson's disease, spastic, rigid muscular hypertonicity, stroke, nervous system laesions, sclerosis multiplex, myelopathies, rachicele or particular pains. A process for the preparation of compound of formula (I) and pharmaceutical compositions containing them are also described.